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Abstract. Vibrio vulnificus, a highly virulent marine bacterium, is the causative agent of both serious
wound infections and fatal septicemia in many areas of the word. A gene (hlyIII) encoding a hemolysin
was cloned and sequenced from V. vulnificus. Nucleotide sequence analysis predicted an open reading
frame of 642 bp encoding a 214 amino acid polypeptide that showed 48% sequence identity to the
hemolysin III of Bacillus cereus. When HlyIII of V. vulnificus was expressed in Escherichia coli, crude
extracts exhibited hemolytic activity similar to that of hemolysin III from Bacillus cereus. A hlyIII
isogenic mutant was constructed via insertional inactivation and showed an attenuated virulence com-
pared with the wild-type strain when this mutant was administered intraperitoneally in mice.
Vibrio vulnificus is a halophilic Gram-negative bacte-
rium that has emerged as an increasingly important
pathogen capable of causing both serious wound infec-
tions and fatal septicemia in humans [4, 8, 21, 25].
Primary septicemia may be acquired by consuming sea-
food containing this organism, with a mortality rate
exceeding 50%. Infections are associated with exposure
of wounds to seawater, with a mortality rate of about
25% [5, 8, 15]. Although the pathogenic mechanism of
V. vulnificus infection has not been fully delineated,
several potential virulence factors such as capsule poly-
saccharide (CPS) [26, 28, 32], iron-sequestering systems
[18], metalloprotease [16] and type IV leader peptidase-
N-methyltransferase [22] have been described.
Oliver et al. [20] reported that the production of
hemolysin may be significant in the fatal infection
caused by V. vulnificus; and Stelma et al. [27] found that
virulent V. vulnificus isolates produced high titers of
hemolytic activity. Therefore, this suggested that a pro-
tein that possesses hemolytic activity might be a poten-
tial virulence factor. A pore-forming hemolysin (vvhA) is
known to be cytolytic to Chinese hamster ovary (CHO)
cells and to disrupt the membranes of various mamma-
lian erythrocytes [11, 14, 31]. It also has the ability to
enhance vascular permeability and is lethal to mice [11,
12, 17]. However, although correlations between hemo-
lysin (vvhA) and the virulence of V. vulnificus strain have
been reported as mentioned above, an isogenic mutant
deficient in the production of hemolysin (vvhA) was still
virulent in mice, as assayed with several animals [29].
We therefore reasoned that other hemolysins might be
important for the pathogenesis of V. vulnificus.
In this study, we describe the cloning and expression
of hlyIII gene from V. vulnificus that is able to induced
hemolytic activity in Escherichia coli. Moreover, we
also created a hlyIII knockout V. vulnificus strain that
was found to be less virulent than the wild-type in mice.
Materials and Methods
Bacterial strains and plasmids. Escherichia coli HB101 (New En-
gland Biolabs, Beverly, MA) was used as host strain for the cloning
experiment. E. coli S17-1pir was used as host strain for the conjuga-
tion experiment [13]. V. vulnificus CKM-1 is clinical isolate from the
blood of a septicemic patient at the Hospital Center of National Cheng-
Kung University [9]. V. vulnificus HLY-1, a hlyIII isogenic mutant, was
derived from the parent strain CKM-1. Plasmid pUC19 (New England
Biolabs) was used in the cloning experiment; plasmid pCVD442 [10]
was used in the gene inactivation experiment. All strains were routinely
grown in minimal medium (12.8 g/L Na2HPO4  7H2O, 3 g/L KH2PO4,
10 g/L NaCl, 1 g/L NH4Cl, 2 mM MgSO4, 0.2 mM CaCl2, 4 g/L
glucose) or Luria–Bertani (LB) medium at 37°C with aeration. Anti-
biotics were used as follows: ampicillin at 100 g/mL for E. coli, and
ampicillin at 100 g/mL and rifampicin 50 g/mL for V. vulnificus.
Molecular techniques. Standard techniques were used to constructCorrespondence to: C.L. Jeang; email: cljeang@nchu.edu.tw
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recombinant plasmids [24]. DNA fragments used in cloning were
extracted from agarose gels by using the Qiaex II kit (Qiagen, Missis-
saugua, Ontario, Canada). PCR was carried out according to the man-
ufacturer’s recommendations by using the Taq DNA polymerase kit
(Amersham Pharmacia Biotech, Uppsala, Sweden). Nucleotide se-
quence was determined by an autosequencer (ABI Prism 373 DNA
Sequencer, Applied Biosystems).
Cloning of Vibrio vulnificus hlyIII gene. The complete coding se-
quence of hlyIII was cloned from the genomic library of CKM-1 strain
[9] with a [-32P]-labeled DNA fragment of hlyIII by colony hybrid-
ization [24]. One positive plasmid (pYC4) was selected for DNA
sequencing.
Expression of hlyIII in E. coli. A 1346 bp fragment containing hlyIII
gene was amplified from pYC4 by PCR with the primers HF1 (5-
CGGGTACCATTGGTGATGCCAAAG-3) and HR1 (5-AA-
GAGCTCACCTTATTGGTGCTAT-3). PCR product was digested
with KpnI and SacI and inserted into identically digested pUC19. The
resulting plasmid, pYC5, was introduced into calcium-competent E.
coli HB101. Exponentially growing bacteria of E. coli HB101 bearing
plasmid pYC5 or pUC19 were induced with 1 mM isopropyl-1-thio--
D-galactopyranoside (IPTG) for 10 h at 37°C. The extract was sepa-
rated by sodium dodecyl sulfate–10% polyacrylamide gel electrophore-
sis (SDS-PAGE) and stained with Coomassie blue.
Hemolytic activity assay. Hemolytic activity assay was carried out
according to the method described by Baida and Kuzmin [3].
Construction of hlyIII mutant. A 199 bp internal fragment of hlyIII
gene of V. vulnificus CKM-1 was generated by PCR with primers HF2
(5-CATGTCGACTAGCTGACCATTGCG-3) and HR2 (5-AAG-
GCATGCGCTAACTCACCAGC-3). The PCR product was digested
with SalI and SphI, and inserted into identically digested pCVD442.
The resulting plasmid (pYC6) was transformed into E. coli S17-1pir
and subsequently transferred into V. vulnificus CKM-1 via conjugation
according to the method described by Hensel et al. [13] with minor
modifications. Transconjugants were selected by ampicillin and rifam-
picin. The resultant strain HLY-1 was further confirmed by PCR and
Southern blot analysis using hlyIII probe.
Reverse transcription-PCR (RT-PCR). SV total RNA isolation kit
(Promega, Madison, WI) was used to extract RNA from wild-type
CKM-1 and hlyIII mutant strains that had been grown in LB broth for
5 h at 37°C. Random hexamers were used to anneal to purified RNA (1
g) for first-strain cDNA synthesis with Superscript II RNase H
reverse transcriptase (Invitrogen, Carlsbad, CA) according to the man-
ufacturer’s instructions. PCR amplifications were performed with Taq
DNA polymerase (Invitrogen) using an aliquot (1/10) of each RT
reaction mixture as templates. hlyIII cDNA was amplified with primers
HF2 (5-CATGTCGACTAGCTGACCATTGCG-3) and HR2 (5-
AAGGCATGCGCTAACTCACCAGC-3), and 16S rRNA cDNA was
amplified with primers UFUL (5-GCCTAACACATGCAAGTCGA-
3) and URUL (5-CGTATTACCGCGGCTGCTGG-3) described by
Nilsson et al. [19]. Thirty cycles of amplification were carried out, and
each cycle consisted of denaturation at 95°C for 1 min, annealing at
55°C for 1 min, and extension at 72°C for 1 min. RNA submitted to
PCR without prior reverse transcription was used as negative control.
16S rRNA was used as internal control. PCR product was electropho-
resed on 2% agarose gel and photographed under UV transillumination.
DNA sequences of these amplified products were confirmed by DNA
sequencing.
PCR. Chromosomal DNAs (100 ng/L) were used as PCR templates.
A pair of oligodeoxyribonucleotides (HF2 and HR2) were used as PCR
primers. PCR was carried out as described above.
Virulence assay. BALB/c mice, 8 to 10 weeks old, purchased from the
animal center of the College of Medicine at National Cheng-Kung
University, were challenged by intraperitoneal injection of the bacterial
suspension. A group of eight mice was given 0.2 mL of a 10-fold
serially diluted bacterial suspension in phosphate-buffered saline per
mouse and mortality was recorded 5 days postinfection. The doses
lethal to 50% of the mice (LD50) of each strain were calculated by the
method of Reed and Muench [23].
Nucleotide sequence accession number. The nucleotide sequence of
hlyIII of V. vulnificus has been assigned GenBank accession number
AY293743.
Results and Discussion
Cloning of V. vulnificus hlyIII gene. During the se-
quencing of a clone containing a serum-resistant gene
(trkA) of V. vulnificus CKM-1 [7], a partial DNA se-
quence, which exhibited homology to hemolysin III of
Bacillus cereus [2], was noted. To isolate clones con-
taining the complete coding sequence of hemolysin III
(hlyIII) from V. vulnificus, a genomic library of CKM-1
DNA in the vector pBR322 was subjected to colony
hybridization and probing with the radiolabeled C-termi-
nal DNA fragment of hlyIII of V. vulnificus; several
probe-reactive clones were isolated. A plasmid pYC4
containing a 5 kb insert was selected for sequence
analysis. Nucleotide sequence analysis predicted an open
reading frame of 642 bp encoding a 214 amino acid
polypeptide with a molecular mass of 23.5 kDa. Analysis
of the deduced amino acid sequence of HlyIII for ho-
mology to known gene sequences in databases using the
BLAST algorithm [1] was performed and several rele-
vant sequences were identified. The amino acid sequence
of HlyIII shared 48% sequence identity (69% similarity)
to the hemolysin III from B. cereus (accession number
P54176) [2] and 80% sequence identity to a putative
hemolysin from V. cholerae (NP_229699). HlyIII also
showed identities to putative hemolysins of other bacte-
ria, including Salmonella typhimurium (71%;
NP_461965.1), Yersinia pestis (66%; NP_404519.1),
Bacillus anthracis (48%; NP_656106.1) and Xanthomo-
nas campestris (47%; NP_638208.1).
Expression of the HlyIII protein in E. coli transfor-
mants. Expression of hlyIII upon induction with IPTG in
E. coli HB101 carrying plasmid pYC5 is shown in Fig. 1.
No major polypeptides could be detected in E. coli
carrying only the pUC19 vector. The expressed hlyIII
gene product migrated as a 23 kDa polypeptide, which
agreed well with the value calculated from the putative
amino acid sequence.
Hemolytic activity. To further investigate the hlyIII
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gene encoding a protein responsible for hemolysis, the
hemolytic activities of E. coli HB101 carrying pYC5 or
pUC19 were compared. The HlyIII-induced hemolysis
began after 3 min and was completed by 12 min of
incubation at 37°C, but hemolytic activity was not ob-
served in the negative control plasmid pUC19 (Fig. 2).
These results showed that recombinant HlyIII exhibited
hemolytic activity.
It has previously been reported that B. cereus hemo-
lysin III acts as an oligomeric pore-forming hemolysin
[3]. Since the putative amino acid sequence of V. vulni-
ficus HlyIII showed 48% identity to hemolysin III of B.
cereus [2], it is reasonable to conjecture that V. vulnificus
HlyIII could also be a pore-forming hemolysin. How-
ever, additional work is needed to determine whether this
is the case.
Isolation of the hlyIII mutant. To determine whether
the hlyIII gene is an important virulence factor in vivo,
we created an insertional inactivation mutant of hlyIII in
strain V. vulnificus CKM-1, as described in Materials and
Methods. Insertional disruption of hlyIII gene in the
HLY-1 strain was checked by PCR using a pair of
primers complementary to sequences located in the hlyIII
and ampicillin-resistant genes (data not shown). To de-
termine whether expression of the hlyIII gene had been
impaired, RT-PCR analysis of the parental and HLY-1
strains was performed. The results of RT-PCR yielded
products of the expected sizes (199 bp) from the RNA of
wild-type strain CKM-1 and that these amplified prod-
ucts were indeed the hlyIII was confirmed by DNA
sequencing. In contrast, no amplification product was
detected from the hlyIII mutant. The result of RT-PCR
analysis confirmed the absence of HlyIII in the hlyIII
mutant (Fig. 3). RNA submitted to PCR without prior
reverse transcription was used as a negative control. No
amplification product was observed in the negative con-
trol (data not shown).
On the other hand, the hlyIII mutant and wild-type
showed identical growth rates under aerobic conditions
in LB medium (data not shown). The result showed that
hlyIII disruption did not appear to cause a growth defect
in vitro. In addition, the HLY-1 strain had an opaque
colony morphology and could grow in minimal medium
similar to wild type CKM-1, suggesting that the hlyIII
mutant HLY-1 probably was neither an unencapsulated
mutant nor an auxotrophic mutant.
The hemolytic activities of the V. vulnificus hlyIII
mutant and wild-type parent strain were compared on
blood agar plates. No major differences between the two
strains were observed after growth on 5% sheep blood
agar plates. There are two possibilities to explain this
phenomenon: (i) HlyIII in V. vulnificus is not expressed
Fig. 1. Expression of hlyIII in E. coli HB101. Lane 1, crude extracts
from E. coli HB101 carrying pYC5; lane 2, crude extracts from E. coli
HB101 carrying pUC19; M, molecular weight markers.
Fig. 2. Hemolysin (HlyIII)-induced hemolysis in a human erythrocyte
suspension at 37°C. Crude proteins from E. coli containing pYC5
(filled symbols) or pUC19 (open symbols) were mixed with equal
volumes of erythrocyte suspension and the mixtures incubated at 37°C
for the indicated time periods. Percentage hemolysis was calculated as
a ratio of A540 of hemolysis control. Data were expressed as the
mean  standard error of a representative experiment performed in
duplicate.
Fig. 3. Confirmation of the V. vulnificus hlyIII mutant by RT-PCR.
RNAs isolated from V. vulnificus CKM-1 (lanes 3 and 5) and the hlyIII
mutant (lanes 4 and 6) were used as template to generate cDNAs.
Genomic DNA PCR was included as positive control (lanes 1 and 2).
Primers HF2 and HR2, specific for hlyIII, produced in a band of 199 bp
(lanes 1, 3 and 4); and primers UFUL and URUL, specific for 16S
rRNA, resulted in a band of 492 bp (lanes 2, 5 and 6). The 16S rRNA
served as an internal control for the presence of RNA used in each
reaction.
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to a significant extent on blood agar plate and (ii) V.
vulnificus may contain other proteins that can compen-
sate for the loss of HlyIII. To our knowledge, V. vulni-
ficus possesses at least two hemolytic proteins other than
hlyIII. One (vvhA) is a pore-forming hemolysin [11, 14]
and the other (vllY) exhibits sequence homology to 4-hy-
droxyphenylpyruvate dioxygenase family proteins [6].
This may explain why the level of hemolysis is similar
between the wild-type and hlyIII mutant on blood agar
plates.
Virulence in mice. The virulence of the hlyIII isogenic
mutant HLY-1 and wild-type strain CKM-1 were studied
by intraperitoneal infection of BALB/c mice. The LD50
value of the mutant HLY-1 in normal mice was 8.0 	
106 at 72 h. This was a 16-fold increase compared with
the LD50 value of 5.0 	 105 for the wild-type in mouse.
Conservation of the hlyIII gene among clinical V.
vulnificus isolates. To elucidate whether hlyIII is com-
mon to clinical V. vulnificus isolates, a pair of PCR
primers (HF2 and HR2) were designed to amplify a 199
bp region within the ORF of hlyIII. The test set of 16 V.
vulnificus isolates included 11 clinical isolates and five
environmental isolates. All the isolates, except one en-
vironmental isolate, produced an amplification product
(Fig. 4). This result demonstrates that hlyIII could po-
tentially play a role in pathogenicity.
A variety of endotoxins and exotoxins have been
implicated as putative virulence factors for V. vulnificus,
including polysaccharide capsules [26, 28, 32], metallo-
protease [16], and cytolysin [11]. CPS has been shown to
play a role in mouse virulence in V. vulnificus [26, 32].
Opaque-to-translucent colony variations are associated
with CPS production. Opaque colonies are encapsulated
while translucent colonies have little or no capsule pro-
duction [32]. Since the hlyIII mutant exhibited an opaque
colony phenotype on LB agar, it is likely that the mouse
virulence of hlyIII mutant was due to the loss of HlyIII
but not CPS. However, because it is known that some V.
vulnificus isolates that express less CPS still form opaque
colonies on LB agar [30], at present we cannot exclude
the possibility that the hlyIII mutant produces less CPS
than wild-type strain; this remains to be determined. No
exotoxin has previously been identified as a virulence
factor in an animal model by gene disruption. In this
study, we identified HlyIII of V. vulnificus as a virulence
factor in mice, although it has not yet been investigated
whether HlyIII is an exotoxin during infection.
In summary, we showed that a recombinant hemo-
lysin (hlyIII) produced from E. coli exhibits hemolytic
activity. In addition, we also created an isogenic inser-
tionally inactivated hlyIII mutant that exhibited attenu-
ated virulence in mice compared with the wild-type
strain. This is the first study to report the relationship
between HlyIII and the virulence of V. vulnificus in mice.
Additional studies are needed to investigate the role of
HlyIII in pathogenesis during infection with V. vulnificus
in vivo.
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